Evidence map›Paper›PMID 33292789›Full record

ArticleDiagnostic and prognostic research2020

Critical appraisal and external validation of a prognostic model for survival of people living with HIV/AIDS who underwent antiretroviral therapy.

Junfeng Wang, Tanwei Yuan, Xuemei Ling, Quanmin Li, Xiaoping Tang, Weiping Cai, Huachun Zou, Linghua Li

Open access · goldAbstract read
In one paragraph

Article in Diagnostic and prognostic research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Junfeng WangJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Universiteitsweg 100, 3584 CG, Utrecht, the Netherlands. j.wang-4@umcutrecht.nl.
Tanwei YuanSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China.
Xuemei LingGuangzhou Eighth People's Hospital, Guangzhou Medical University, No.627 Dongfeng Dong Road, Guangzhou, 510060, Guangdong, China.
Quanmin LiGuangzhou Eighth People's Hospital, Guangzhou Medical University, No.627 Dongfeng Dong Road, Guangzhou, 510060, Guangdong, China.
Xiaoping TangGuangzhou Eighth People's Hospital, Guangzhou Medical University, No.627 Dongfeng Dong Road, Guangzhou, 510060, Guangdong, China.
Weiping CaiGuangzhou Eighth People's Hospital, Guangzhou Medical University, No.627 Dongfeng Dong Road, Guangzhou, 510060, Guangdong, China.
Huachun ZouSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China. zouhuachun@mail.sysu.edu.cn.
Linghua LiGuangzhou Eighth People's Hospital, Guangzhou Medical University, No.627 Dongfeng Dong Road, Guangzhou, 510060, Guangdong, China. llheliza@126.com.
Guangzhou Eighth People's Hospital · CNGuangzhou Medical University · CNSun Yat-sen University · CNUNSW Sydney · AUUtrecht University · NL

Funding

Natural Science Foundation of China Excellent Young Scientists Fund 82022064Natural Sience Foundation of China International/Regional Research Collaboration Project 72061137001Natural Sience Foundation of China Young Scientist Fund 81703278the 13th Five-Year Key Special Project of Ministry of Science and Technology 2018ZX10715004the Australian National Health and Medical Research Commission (NHMRC) Early Career Fellowship APP1092621the High Level Project of Medicine in Longhua, Shenzhen HLPM201907020105the Joint-innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou 201803040002the National Key Research and Development Program of China 2020YFC0840900the National Science and Technology Major Project of China 2018ZX10721102the National Special Research Program of China for Important Infectious Diseases 2018ZX10302103-002the Sanming Project of Medicine in Shenzhen SZSM201811071
6 · The paper itself

Abstract

backgroundHIV/AIDS remains a leading cause of death worldwide. Recently, a model has been developed in Wenzhou, China, to predict the survival of people living with HIV/AIDS (PLWHA) who underwent antiretroviral therapy (ART). We aimed to evaluate the methodological quality and validate the model in an external population-based cohort.

methodsPrediction Model Risk of Bias Assessment Tool (PROBAST) was used to assess the risk of bias of the Wenzhou model. Data were from the National Free Antiretroviral Treatment Program database. We included PLWHA treated between February 2004 and December 2019 in a tertiary hospital in Guangzhou city, China. The endpoint was all-cause deaths and assessed until January 2020. We assessed the discrimination performance of the model by Harrell's overall C-statistics and time-dependent C-statistics and calibration by comparing observed survival probabilities estimated with the Kaplan-Meier method versus predicted survival probabilities. To assess the potential prediction value of age and gender which were precluded in developing the Wenzhou model, we compared the discriminative ability of the original model with an extended model added with age and gender.

resultsBased on PROBAST, the Wenzhou model was rated as high risk of bias in three out of the four domains (selection of participants, definition of outcome, and methods for statistical analysis) mainly because of the misuse of nested case-control design and propensity score matching. In the external validation analysis, 16758 patients were included, among whom 743 patients died (mortality rate 11.41 per 1000 person-years) during follow-up (median 3.41 years, interquartile range 1.64-5.62). The predictor of HIV viral load was missing in 14361 patients (85.7%). The discriminative ability of the Wenzhou model decreased in the external dataset, with the Harrell's overall C-statistics being 0.76, and time-dependent C-statistics dropping from 0.81 at 6 months to 0.48 at 10 years after ART initiation. The model consistently underestimated the survival, and the level was 6.23%, 10.02%, and 14.82% at 1, 2, and 3 years after ART initiation, respectively. The overall and time-dependent discriminative ability of the model improved after adding age and gender to the original model.

conclusionThe Wenzhou prognostic model is at high risk of bias in model development, with inadequate model performance in external validation. Thereby, we could not confirm the validity and extended utility of the Wenzhou model. Future prediction model development and validation studies need to comply with the methodological standards and guidelines specifically developed for prediction models.

Indexed as

External validationPeople living with HIV/AIDSPrognostic modelSurvival

Identifiers

PMID33292789
PMCPMC7687783
OpenAlexW3109887023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.